Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience

BACKGROUND: Adalimumab is proven to be safe and effective in treating plaque psoriasis. A biosimilar adalimumab (ZRC-3197; Exemptia™) - approved by Indian Regulators in 2014 - is a 'fingerprint match' of the reference adalimumab in terms of purity, potency, safety, and clinical efficacy. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Chopra, Ajay, Mitra, Debdeep, Agarwal, Reetu, Saraswat, Neerja, Chemburkar, Pooja, Sharma, Loknandini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247647/
https://www.ncbi.nlm.nih.gov/pubmed/32477976
http://dx.doi.org/10.4103/idoj.IDOJ_120_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247647/
https://www.ncbi.nlm.nih.gov/pubmed/32477976
http://dx.doi.org/10.4103/idoj.IDOJ_120_19

Ejemplares similares